Free tool
FAERS Monitor: Celestone Soluspan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 014602 or its brand name (Celestone Soluspan, Betamethasone Acetate, Betamethasone Sodium Phosphate). Reports on generic versions are filed under their own applications.
Reports
397
Serious
177
45% of reports
Hospitalization
64
Death reported
9
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- maternal exposure during pregnancy122
- product use in unapproved indication28
- drug ineffective21
- exposure during pregnancy20
- no adverse event20
- pain17
- anxiety15
- headache14
- dizziness13
- fatigue12
- insomnia12
- anaphylactic reaction11
- dyspnoea11
- nausea11
- off label use11
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 19 |
| 2006 | 10 |
| 2007 | 4 |
| 2008 | 9 |
| 2009 | 16 |
| 2010 | 6 |
| 2011 | 7 |
| 2012 | 5 |
| 2013 | 16 |
| 2014 | 14 |
| 2015 | 11 |
| 2016 | 41 |
| 2017 | 24 |
| 2018 | 30 |
| 2019 | 40 |
| 2020 | 42 |
| 2021 | 37 |
| 2022 | 27 |
| 2023 | 14 |
| 2024 | 9 |
| 2025 | 3 |
| 2026 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,762 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| maternal exposure during pregnancySignal | 122 | 72.6 | 62.6 | 8,570 |
| exposure during pregnancySignal | 20 | 17.1 | 11.1 | 287 |
| anaphylactic reactionSignal | 11 | 10.5 | 5.9 | 86 |
| product use in unapproved indicationSignal | 28 | 6.0 | 4.2 | 113 |
| no adverse eventSignal | 20 | 5.8 | 3.8 | 76 |
| anxietySignal | 15 | 2.8 | 1.7 | 16 |
| insomniaSignal | 12 | 2.4 | 1.4 | 8 |
| pain | 17 | 1.5 | 0.9 | 2 |
| dizziness | 13 | 1.4 | 0.8 | 1 |
| headache | 14 | 1.2 | 0.7 | 0 |
| dyspnoea | 11 | 1.0 | 0.6 | 0 |
| drug ineffective | 21 | 0.8 | 0.6 | 0 |
| fatigue | 12 | 0.8 | 0.5 | 0 |
| nausea | 11 | 0.7 | 0.4 | 1 |
| off label use | 11 | 0.7 | 0.4 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.